Serdemetan (JNJ-26854165)

目录号：S1172 Purity: 99.58%

Serdemetan (JNJ-26854165)是一种HDM2泛素连接酶拮抗剂，作用于p53野生型细胞，诱导早期凋亡，在缺乏功能性p53的细胞中，抑制细胞增殖而延迟细胞凋亡。

Serdemetan (JNJ-26854165) Chemical Structure

CAS: 881202-45-5

规格	价格	库存
5mg	903.65	现货
25mg	3012.66	现货
100mg	7931.79	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.58%

99.58

Serdemetan (JNJ-26854165)相关产品

相关产品	Pifithrin-α (PFTα) HBr Pifithrin-μ Eprenetapopt (APR-246) RITA CBL0137 HCl PRIMA-1 NSC 319726 (ZMC1) Tenovin-1 Tenovin-6 NSC348884 NSC59984 Cyclic Pifithrin-α hydrobromide COTI-2 Kevetrin hydrochloride ReACp53	点击展开
相关化合物库	自噬化合物库凋亡分子化合物库铁死亡化合物库细胞焦亡化合物库线粒体靶向化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	活性描述	文献信息
KU-19-19 cell	Growth inhibition assay	Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50=0.93236 μM	SANGER
H4 cell	Growth inhibition assay	Inhibition of human H4 cell growth in a cell viability assay, IC50=1.06707 μM	SANGER
KGN cell	Growth inhibition assay	Inhibition of human KGN cell growth in a cell viability assay, IC50=1.6205 μM	SANGER
786-0 cell	Growth inhibition assay	Inhibition of human 786-0 cell growth in a cell viability assay, IC50=1.72989 μM	SANGER
769-P cell	Growth inhibition assay	Inhibition of human 769-P cell growth in a cell viability assay, IC50=1.82224 μM	SANGER
K5 cell	Growth inhibition assay	Inhibition of human K5 cell growth in a cell viability assay, IC50=2.01624 μM	SANGER
MLMA cell	Growth inhibition assay	Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50=2.03217 μM	SANGER
MLMA cell	Growth inhibition assay	Inhibition of human MLMA cell growth in a cell viability assay, IC50=2.28703 μM	SANGER
EW-7 cell	Growth inhibition assay	Inhibition of human EW-7 cell growth in a cell viability assay, IC50=2.32695 μM	SANGER
SW1088 cell	Growth inhibition assay	Inhibition of human SW1088 cell growth in a cell viability assay, IC50=2.80651 μM	SANGER
MC-IXC cell	Growth inhibition assay	Inhibition of human MC-IXC cell growth in a cell viability assay, IC50=2.87792 μM	SANGER
NCI-H2052 cell	Growth inhibition assay	Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50=3.08157 μM	SANGER
IGR-1 cell	Growth inhibition assay	Inhibition of human IGR-1 cell growth in a cell viability assay, IC50=3.12028 μM	SANGER
DSH1 cell	Growth inhibition assay	Inhibition of human DSH1 cell growth in a cell viability assay, IC50=3.24296 μM	SANGER
PA-1 cell	Growth inhibition assay	Inhibition of human PA-1 cell growth in a cell viability assay, IC50=3.30059μM	SANGER
SK-MEL-3 cell	Growth inhibition assay	Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=3.31207 μM	SANGER
SW900 cell	Growth inhibition assay	Inhibition of human SW900 cell growth in a cell viability assay, IC50=3.48255 μM	SANGER
CAKI-1 cell	Growth inhibition assay	Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50=3.52738 μM	SANGER
ES1 cell	Growth inhibition assay	Inhibition of human ES1 cell growth in a cell viability assay, IC50=3.52897 μM	SANGER
SK-N-DZ cell	Growth inhibition assay	Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=3.62595 μM	SANGER
RH-1 cell	Growth inhibition assay	Inhibition of human RH-1 cell growth in a cell viability assay, IC50=3.68463 μM	SANGER
ES8 cell	Growth inhibition assay	Inhibition of human ES8 cell growth in a cell viability assay, IC50=3.69702 μM	SANGER
NEC8 cell	Growth inhibition assay	Inhibition of human NEC8 cell growth in a cell viability assay, IC50=3.76982 μM	SANGER
LNCaP-Clone-FGC cell	Growth inhibition assay	Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50=3.83536 μM	SANGER
HCE-4 cell	Growth inhibition assay	Inhibition of human HCE-4 cell growth in a cell viability assay, IC50=3.9807 μM	SANGER
U-118-MG cell	Growth inhibition assay	Inhibition of human U-118-MG cell growth in a cell viability assay, IC50=4.01066 μM	SANGER
GI-ME-N cell	Growth inhibition assay	Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50=4.08796 μM	SANGER
LB1047-RCC cell	Growth inhibition assay	Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=4.16143 μM	SANGER
HT-1080 cell	Growth inhibition assay	Inhibition of human HT-1080 cell growth in a cell viability assay, IC50=4.19921 μM	SANGER
NB69 cell	Growth inhibition assay	Inhibition of human NB69 cell growth in a cell viability assay, IC50=4.35047 μM	SANGER
NCI-H1693 cell	Growth inhibition assay	Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50=4.44895 μM	SANGER
HSC-3 cell	Growth inhibition assay	Inhibition of human HSC-3 cell growth in a cell viability assay, IC50=4.49933 μM	SANGER
MDA-MB-231 cell	Growth inhibition assay	Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50=4.55899 μM	SANGER
HOS cell	Growth inhibition assay	Inhibition of human HOS cell growth in a cell viability assay, IC50=4.7863 μM	SANGER
BT-549 cell	Growth inhibition assay	Inhibition of human BT-549 cell growth in a cell viability assay, IC50=4.7887 μM	SANGER
NB17 cell	Growth inhibition assay	Inhibition of human NB17 cell growth in a cell viability assay, IC50=4.78976 μM	SANGER
5637 cell	Growth inhibition assay	Inhibition of human 5637 cell growth in a cell viability assay, IC50=4.79652 μM	SANGER
OVCAR-8 cell	Growth inhibition assay	Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50=4.92436 μM	SANGER
G-402 cell	Growth inhibition assay	Inhibition of human G-402 cell growth in a cell viability assay, IC50=4.93035 μM	SANGER
BB30-HNC cell	Growth inhibition assay	Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=5.07218 μM	SANGER
HCC1806 cell	Growth inhibition assay	Inhibition of human HCC1806 cell growth in a cell viability assay, IC50=5.08339 μM	SANGER
COLO-800 cell	Growth inhibition assay	Inhibition of human COLO-800 cell growth in a cell viability assay, IC50=5.1264 μM	SANGER
FADU cell	Growth inhibition assay	Inhibition of human FADU cell growth in a cell viability assay, IC50=5.36557 μM	SANGER
NCI-H1651 cell	Growth inhibition assay	Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50=5.39409 μM	SANGER
AGS cell	Growth inhibition assay	Inhibition of human AGS cell growth in a cell viability assay, IC50=5.47711 μM	SANGER
CHP-212 cell	Growth inhibition assay	Inhibition of human CHP-212 cell growth in a cell viability assay, IC50=5.39409 μM	SANGER
YAPC cell	Growth inhibition assay	Inhibition of human YAPC cell growth in a cell viability assay, IC50=5.47711 μM	SANGER
GOTO cell	Growth inhibition assay	Inhibition of human GOTO cell growth in a cell viability assay, IC50=5.49576 μM	SANGER
KYSE-510 cell	Growth inhibition assay	Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50=5.511 μM	SANGER
NCI-H2342 cell	Growth inhibition assay	Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50=5.53278 μM	SANGER
BFTC-905 cell	Growth inhibition assay	Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=5.62835 μM	SANGER
EW-16 cell	Growth inhibition assay	Inhibition of human EW-16 cell growth in a cell viability assay, IC50=5.72093 μM	SANGER
SK-MEL-30 cell	Growth inhibition assay	Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50=5.74543 μM	SANGER
HLE cell	Growth inhibition assay	Inhibition of human HLE cell growth in a cell viability assay, IC50=5.77489 μM	SANGER
T98G cell	Growth inhibition assay	Inhibition of human T98G cell growth in a cell viability assay, IC50=5.79635 μM	SANGER
HUTU-80 cell	Growth inhibition assay	Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=5.84228 μM	SANGER
NOS-1 cell	Growth inhibition assay	Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=5.94766 μM	SANGER
SW780 cell	Growth inhibition assay	Inhibition of human SW780 cell growth in a cell viability assay, IC50=5.96949 μM	SANGER
KYSE-180 cell	Growth inhibition assay	Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50=5.97654 μM	SANGER
MDA-MB-361 cell	Growth inhibition assay	Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50=5.98647 μM	SANGER
SNU-C2B cell	Growth inhibition assay	Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50=6.01138 μM	SANGER
NCI-H661 cell	Growth inhibition assay	Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50=6.0694 μM	SANGER
OE33 cell	Growth inhibition assay	Inhibition of human OE33 cell growth in a cell viability assay, IC50=6.14389 μM	SANGER
TYK-nu cell	Growth inhibition assay	Inhibition of human TYK-nu cell growth in a cell viability assay, IC50=6.21863 μM	SANGER
COLO-792 cell	Growth inhibition assay	Inhibition of human COLO-792 cell growth in a cell viability assay, IC50=6.25219 μM	SANGER
HEL cell	Growth inhibition assay	Inhibition of human HEL cell growth in a cell viability assay, IC50=6.2676 μM	SANGER
D-566MG cell	Growth inhibition assay	Inhibition of human D-566MG cell growth in a cell viability assay, IC50=6.33491 μM	SANGER
U031 cell	Growth inhibition assay	Inhibition of human U031 cell growth in a cell viability assay, IC50=6.41816 μM	SANGER
COR-L23 cell	Growth inhibition assay	Inhibition of human COR-L23 cell growth in a cell viability assay, IC50=6.43346 μM	SANGER
NCI-H2452 cell	Growth inhibition assay	Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50=6.52281 μM	SANGER
BB65-RCC cell	Growth inhibition assay	Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=6.6459 μM	SANGER
CAL-33 cell	Growth inhibition assay	Inhibition of human CAL-33 cell growth in a cell viability assay, IC50=6.65665 μM	SANGER
点击查看更多细胞系数据

生物活性

产品描述

Serdemetan (JNJ-26854165)是一种HDM2泛素连接酶拮抗剂，作用于p53野生型细胞，诱导早期凋亡，在缺乏功能性p53的细胞中，抑制细胞增殖而延迟细胞凋亡。

特性

JNJ 26854165是口服生物有效性的，小分子HDM2拮抗剂，具有有效的抗肿瘤活性。

靶点

p53 ^[1]
(Cell-free assay)

HDM2 ^[1]
(Cell-free assay)

Mdm2 ^[2]
(Cell-free assay)

体外研究(In Vitro)
体外研究活性	JNJ-26854165是新型激活p53的色胺衍生物，作为HDM2泛素连接酶拮抗剂。JNJ-26854165作用于白血病细胞系，抑制细胞生长，且诱导凋亡，作用于OCI-AML-3, MOLM-13,NALM-6和REH细胞72小时后，IC50值分别为0.24,0.33,0.32和0.44 µM。此外, JNJ-26854165作用于p53突变的细胞，加速蛋白酶调节的p21降解和抗p53对p21的转录诱导, 诱导S期延迟，且上调E2F1表达, 导致S期细胞优先凋亡。^[1] JNJ-26854165是口服MDM2抑制剂，可以抑制MDM2-p53复合体与蛋白酶的相互作用，且通过与MDM2的RING域结合提高p53水平。^[2]最新研究显示JNJ-26854165作用于四种人类癌细胞系:H460,A549,p53-WT-HCT116,和p53-null-HCT116，抑制无性繁殖生存。^[3]
细胞实验	细胞系	OCI-AML-3,MOLM-13,NB4和U937细胞
	浓度	0到10 μM
	孵育时间	72 小时
	方法	细胞系维持在含10%热灭活胎牛血清(FCS)的RPMI 1640培养基上。急性骨髓性白血病(AML) 患者体内得到的OCI-AML-3, MOLM-13, NB4和 U937 细胞,慢性髓细胞性白血病(CML)患者体内得到的K562细胞,急性成淋巴细胞性白血病(ALL)患者体内得到的NALM-6, REH, P12-ICHIKAWA和PF-382细胞。OCI-AML-3, MOLM-13, NALM-6和 REH 细胞具有野生型p53, 然而NB4,U937,K562,P12-ICHIKAWA和PF-382细胞具有突变型p53，获得对数生长期细胞系，接种，用JNJ-26854165处理。白血病患者体内获得的白血病细胞中获得肝素外周血或骨髓样本。通过密度梯度离心纯化单核细胞，非黏着细胞悬浮在含10%FCS的RPMI 1640培养基上。正常骨髓衍生的干细胞接种在含MEM-α培养基的12孔板上，24小时后，加入AML细胞。为了研究骨髓干细胞作用于原代白血病细胞的效果，培养AML 细胞。在JNJ-26854165和 AraC的联合实验中,用0,2,5或 10 μM。JNJ-26854165 处理AML细胞系。在OCI-AML-3细胞中 JNJ-26854165与 AraC的浓度比为1:1，在其他细胞中为10:1。两种试剂同时加到细胞中，培养48小时。JNJ-26854165和Doxorubicin联用的实验中,两种试剂同时加到细胞中，培养48小时。用 0, 25, 50或 100 nM Doxorubicin处理细胞 (用0,100,200 或400 nM Doxorubicin 处理OCI-AML-3细胞和原代白血病细胞)，Doxorubicin 与JNJ-26854165 的浓度比为1:10 (在OCI-AML-3细胞和原代白血病细胞中比为1:25)。通过台酚蓝染料重复计数，测评细胞活力。
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	Bcr-abl / p-Bcr-abl / p-CrkL / STAT5 / p-STAT5 / STAT3 / p-STAT3 MDM2 / p-MDM2 / p53 ABCA1 / ABCG1 / NPC1 / NPC2 / HMGcoR p53 / HDM2 / HDMX / p21 / Noxa / Puma		27999193
	Growth inhibition assay	Cell viability		23820125
	Immunofluorescence	p53		27999193

体内研究(In Vivo)
体内研究活性	JNJ-26854165按20 mg/kg剂量口服饲喂于三十六分之十七(47%)实体移植瘤和七分之五(71%) ALL移植瘤，持续5天，重复进行6周，导致EFS分布出现明显区别。^[4]
动物实验	Animal Models	皮下注射kidney/rhabdoid肿瘤,肉瘤, 成神经细胞瘤, 和非恶性胶质瘤脑癌的雌性CB17SC scid^-/-小鼠，携带神经胶质瘤的BALB/c nu/nu小鼠
	Dosages	≤20 mg/kg
	Administration	口服处理

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT00676910	Completed	Neoplasms	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	November 2006	Phase 1

参考文献
[1] Kojima K, et al. Mol Cancer Ther. 2010, 9(9), 2545-2557. [2] Yuan Y, et al. J Hematol Oncol. 2011, 4:16. [3] Chargari C, et al. Cancer Lett. 2011, 312(2), 209-218. [4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332. + 展开

参考文献

[4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

+ 展开

化学信息&溶解度

分子量	328.41	分子式	C₂₁H₂₀N₄
CAS号	881202-45-5	SDF	Download Serdemetan (JNJ-26854165) SDF
Smiles	C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 66 mg/mL ( (200.96 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 2 mg/mL (6.08 mM)

Water : Insoluble

DMSO : 66 mg/mL ( (200.96 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):